[Cutaneous drug reactions: pharmacogenetic news].
Identifying genetic factors in severe drug eruption should improve efficacy and safety of drug prescription. The first pharmacogenetic studies concerned the polymorphism of genes encoding drug metabolism enzymes (especially for sulfamides reactions in AIDS and anticonvulsants reactions). Recent studies did not confirm the role of genotypic variation in metabolism enzymes in drug reaction. Genes controlling immune response are another research issue. Certain MHC phenotypes are linked to a higher risk of toxidermy, such as in abacavir hypersensitivity or fixed drug eruption. Indeed, severe drug eruptions seem to be linked to a specific immune response controlled by T lymphocytes.
Buffard
V
V
Service de dermatologie, hôpital Henri-Mondor, Créteil, France. valerie.buffard@hmn.ap-hop-paris.fr
Roujeau
J-C
JC
D000927:Anticonvulsants / Q000009:adverse effects; D003875:Drug Eruptions / Q000235:genetics* / Q000503:physiopathology*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008285:Major Histocompatibility Complex / Q000235:genetics / Q000276:immunology; D010597:Pharmacogenetics / Q000639:trends*; D010641:Phenotype; D011110:Polymorphism, Genetic; D013601:T-Lymphocytes
D000927:Anticonvulsants